ATF7 Antibody [Janelia Fluor® 669]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-30071JF669
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Predicted:
Orangutan (100%). Backed by our 100% Guarantee.
Applications
Immunoprecipitation, Western Blot
Label
Janelia Fluor 669
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
maps to a region between residue 444 and 494 of human activating transcription factor 7 using the numbering given in entry CAA40483.1
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for ATF7 Antibody [Janelia Fluor® 669]
Application
Recommended Usage
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: ATF7
Alternate Names
activating transcription factor 7ATFATranscription factor ATF-A, cAMP-dependent transcription factor ATF-7, cyclic AMP-dependent transcription factor ATF-7, MGC57182
Gene Symbol
ATF7
Additional ATF7 Products
Product Documents for ATF7 Antibody [Janelia Fluor® 669]
Product Specific Notices for ATF7 Antibody [Janelia Fluor® 669]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...